After the success of the Research Topic "Recent Developments in Pancreatic Cancer Radiotherapy", we are pleased to announce a second volume of this collection.The field of pancreatic cancer research has been marked by significant challenges, primarily due to the disease's high lethality and the limitations of current treatment methodologies. Despite extensive research, pancreatic cancer remains the fourth leading cause of cancer-related death globally, with a five-year survival rate of less than 9%. The poor prognosis is attributed to late-stage diagnosis due to inadequate screening methods, complex surgical procedures, and high rates of chemoresistance and recurrence. Non-metastatic pancreatic cancer, which can be classified into resectable, borderline resectable, and locally advanced pancreatic cancer (LAPC), presents another layer of complexity. With only 10-20% of patients eligible for surgery and approximately 30% diagnosed as LAPC, the role of radiation therapy becomes crucial, albeit controversial due to the lack of definitive data on the use of adjuvant therapy using modern radiotherapy techniques.
The primary goal of this research topic is to provide updates on the role of radiotherapy in the treatment of pancreatic cancer. The focus is on understanding the optimal radiotherapy fractionation schedule and the total dose necessary to improve the prognosis for pancreatic cancer patients. The research aims to address the existing gaps in knowledge and contribute to the ongoing debates on the effectiveness of radiation therapy in treating pancreatic cancer.
The scope of this research topic is confined to the exploration of radiotherapy in the treatment of pancreatic cancer. We welcome articles addressing, but not limited to, the following themes:
? Delivery techniques for pancreatic cancer, particularly Stereotactic Body Radiation Therapy (SBRT)
? Updates in chemoradiotherapy for pancreatic cancer
? Motion management of pancreatic cancer
? Adverse effects of radiotherapy for pancreatic cancer.
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases without validation (independent cohort or biological validation in vitro or in vivo) will not be accepted.
After the success of the Research Topic "Recent Developments in Pancreatic Cancer Radiotherapy", we are pleased to announce a second volume of this collection.The field of pancreatic cancer research has been marked by significant challenges, primarily due to the disease's high lethality and the limitations of current treatment methodologies. Despite extensive research, pancreatic cancer remains the fourth leading cause of cancer-related death globally, with a five-year survival rate of less than 9%. The poor prognosis is attributed to late-stage diagnosis due to inadequate screening methods, complex surgical procedures, and high rates of chemoresistance and recurrence. Non-metastatic pancreatic cancer, which can be classified into resectable, borderline resectable, and locally advanced pancreatic cancer (LAPC), presents another layer of complexity. With only 10-20% of patients eligible for surgery and approximately 30% diagnosed as LAPC, the role of radiation therapy becomes crucial, albeit controversial due to the lack of definitive data on the use of adjuvant therapy using modern radiotherapy techniques.
The primary goal of this research topic is to provide updates on the role of radiotherapy in the treatment of pancreatic cancer. The focus is on understanding the optimal radiotherapy fractionation schedule and the total dose necessary to improve the prognosis for pancreatic cancer patients. The research aims to address the existing gaps in knowledge and contribute to the ongoing debates on the effectiveness of radiation therapy in treating pancreatic cancer.
The scope of this research topic is confined to the exploration of radiotherapy in the treatment of pancreatic cancer. We welcome articles addressing, but not limited to, the following themes:
? Delivery techniques for pancreatic cancer, particularly Stereotactic Body Radiation Therapy (SBRT)
? Updates in chemoradiotherapy for pancreatic cancer
? Motion management of pancreatic cancer
? Adverse effects of radiotherapy for pancreatic cancer.
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases without validation (independent cohort or biological validation in vitro or in vivo) will not be accepted.